EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Exploring the risk of adverse drug events in combination with antiparkinsonics and antipsychotics—a two-decade real-world pharmacovigilance analysis based on the FAERS database

Junyi Wang, Sen Lin, Chen Bai, Huimin Zhang, Haoqi Liu, Min Wang, Rongjuan Guo iD

International Journal of Neuropsychopharmacology · 06.06.2025 · 28 (6)

DOI: 10.1093/ijnp/pyaf033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 21.05.2025. Verfasst von Junyi Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Beijing University of Chinese Medicine Second Clinical Medical School, Beijing, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Antipsychotic Agents, Adverse Drug Reaction Reporting Systems, Antiparkinson Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Municipal Health Commission, Depression Chinese Medicine and Western Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The combination of antiparkinsonics and antipsychotic drugs (AP) can improve the motor and mental symptoms of Parkinson’s disease (PD) and reduce the actual burden of chronic disease care. To explore the adverse drug events (ADEs) worthy of attention in this treatment management process, we conducted a real-world pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database.

Methods

The Standard pharmacotherapy for PD includes Levodopa/Carbidopa, Entacapone, Rasagiline, Pramipexole, Ropinirole, Rotigotine, Apomorphine, Amantadine, etc. Antipsychotic drug includes Quetiapine, Clozapine, and Pimavanserin. We collected the ADEs reports of FAERS that conformed to the combination regimens of anti-Parkinson’s drugs and AP during the 20-year period from the third quarter of 2004 to the second quarter of 2024. Disproportionate analysis and subgroup analysis were conducted through 5 algorithms, namely Ω shrinkage measure, additive model, multiplicative model, Combination risk ratio, and Chi-square. The time-to-onset (TTO) analysis was used to predict the variation of the risk size of ADEs occurrence over time. Finally, we explored the correlation between population characteristics and the occurrence of ADEs through Logistic regression.

Results

We collected a total of 6297 cases, including 38 316 ADEs records. The results of the disproportionate analysis show that the ADEs with the highest occurrence frequency include hallucination, general physical health deterioration, somnolence, stoma site discharge, urinary tract infection, memory impairment, etc. The TTO analysis results showed that the median TTO for all ADEs was 657.50 days, the median TTO for infection and inflammation was 716.00 days, and the median TTO for psychiatric symptoms was 823.00 days. All median TTOs conform to the early failure curve. The results of Logistic regression showed that gender was correlated with the occurrence of infection and inflammation, and the female population was more inclined to have important medical events related to infection and inflammation.

Conclusions

During the combined application of antiparkinsonics and AP, in addition to ADEs such as movement disorders and emerging mental symptoms, the risks of infection and inflammation should also be given key attention. Long-term follow-up should run through the entire process of disease diagnosis and treatment, and attention should be paid to the influence of drug dosage forms and dosages. The medication plan should be adjusted in a timely manner when ADEs occur.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceAntipsychotic AgentsAdverse Drug Reaction Reporting SystemsAntiparkinson AgentsParkinson DiseaseDrug-Related Side Effects and Adverse ReactionsHumansMaleFemaleMiddle AgedAgedDatabases, FactualDrug Therapy, CombinationAdultUnited States

Stichwörter der Autor:innen

FAERSParkinson’s diseaseadverse drug eventantipsychoticdisproportionality analysispharmacovigilance

Substanzen

Antipsychotic AgentsAntiparkinson Agents

Autor:innen und Institutionen

  • Beijing University of Chinese Medicine Second Clinical Medical School, Beijing, China.
  • The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Department of Neurology II, Beijing University of Chinese Medicine Dongfang Hospital, Beijing, China.

ORCID-Profile: Rongjuan Guo

Förderung

  • Beijing Municipal Health Commission
  • Depression Chinese Medicine and Western Medicine

Zitieren

APA

Wang, J., Lin, S., Bai, C., Zhang, H., Liu, H., Wang, M., & Guo, R. (2025). Exploring the risk of adverse drug events in combination with antiparkinsonics and antipsychotics—a two-decade real-world pharmacovigilance analysis based on the FAERS database. International Journal of Neuropsychopharmacology, 28(6). https://doi.org/10.1093/ijnp/pyaf033

Vancouver

Wang J, Lin S, Bai C, Zhang H, Liu H, Wang M, et al. Exploring the risk of adverse drug events in combination with antiparkinsonics and antipsychotics—a two-decade real-world pharmacovigilance analysis based on the FAERS database. International Journal of Neuropsychopharmacology. 2025;28(6). doi:10.1093/ijnp/pyaf033

BibTeX
@article{Wang2025,
  author = {Wang, Junyi and Lin, Sen and Bai, Chen and Zhang, Huimin and Liu, Haoqi and Wang, Min and Guo, Rongjuan},
  title = {Exploring the risk of adverse drug events in combination with antiparkinsonics and antipsychotics—a two-decade real-world pharmacovigilance analysis based on the FAERS database},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2025},
  volume = {28},
  number = {6},
  doi = {10.1093/ijnp/pyaf033}
}
Kostenlos starten →